Levothyroxine Sodium Drug Asset Due Diligence Report 2026

This Levothyroxine Sodium Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.

Decision date: 15 July 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.

Approved

Highest phase

344

Registered trials

Result records

Matched deals

Executive recommendation: GO

Decision memo

Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.

The central underwriting question is whether Levothyroxine Sodium can convert its Small molecule drug profile and THR biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.

1. Asset identity and development status

Asset	Levothyroxine Sodium (query alias: levothyroxine)
Modality / target	Small molecule drug; THR; THR agonists
Highest global status	Approved
Originator	AbbVie, Inc.
Active developers	Shenzhen Zhonglian Guangzhen Pharmaceutical Group Co. Ltd., BioSyent, Inc., Fresenius Kabi USA LLC

The MCP disease footprint includes Thyroid Diseases, Differentiated Thyroid Gland Carcinoma, Myxedema coma. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.

2. Clinical program: design and endpoint audit

Registry	Phase	Status	Enrollment	Lead primary endpoint
ChiCTR2600125589	Phase 4	Recruiting	91	Spontaneous abortion rate
NCT07625722	Not Applicable	Not yet recruiting	106	Cognitive function evaluated by Bayley-IV
NCT07568574	Not Applicable	Enrolling by invitation	60	The incidence and severity of Treatment-related adverse events (TRAEs), including adverse events (AEs) and serious adverse events (SAEs), as assessed by the study physicians from baseline to 5.5 years after enrollment.

The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.

Reproduce the asset-to-trial workflow with PatSnap MCP

3. Clinical readouts: what is known

A Randomized Comparative Study Between Liquid (Tirosint®-SOL) and Tablet Formulations of Levothyroxine in Neonates and Infants With Congenital Hypothyroidism

Phase 4; n=34; evaluation: not stated. Reported fields: LT4 Dose Required to Maintain TSH in Target Range (Unit: mcg/kg/Day)(Mean): P-Value = 0.0044; LT4 Dose Required to Maintain TSH in Target Range (Unit: mcg/kg/Day)(Mean) = 5.06 mcg/kg/day (Standard Deviation, 1.127); LT4 Dose Required to Maintain TSH in Target Range (Unit: mcg/kg/Day)(Mean) = 3.73 mcg/kg/day (Standard Deviation, 1.469)

Discontinuation of levothyroxine therapy in patients with subclinical hypothyroidism: a pilot randomized clinical trial

Phase 2; n=45; evaluation: Positive. Reported fields: AE = The only notable adverse event was rib fractures in a placebo group participant (TSH 3.04 mIU/L at 6 months). Two participants in the placebo group restarted levothyroxine (n = 1, TSH > 10 mIU/L; n = 1, fatigue). ; AE = The only notable adverse event was rib fractures in a placebo group participant (TSH 3.04 mIU/L at 6 months). Two participants in the placebo group restarted levothyroxine (n = 1, TSH > 10 mIU/L; n = 1, fatigue).

A Phase 2, Multicenter, Non-Randomized, Open-Label, Single Arm, Self-controlled Study of XP-8121 For the Treatment of Adult Subjects With Hypothyroidism

Phase 2; n=46; evaluation: not stated. Reported fields: -; -; -

These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.

4. Market and competitive position

Levothyroxine Sodium addresses Thyroid Diseases, Differentiated Thyroid Gland Carcinoma, Myxedema coma. Commercial attractiveness rests on addressable biomarker-positive patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Small molecule drug—must demonstrate a benefit large enough to offset class-specific safety and operational costs.

The strongest market-validation signal in this screen is partner behavior: 4 matched transaction record(s) indicate that sophisticated counterparties have assigned strategic value to the asset or its rights. That does not establish net present value; probability of success, remaining R&D spend, royalties, cost sharing and territorial scope still need modeling.

5. Transaction precedent and economics

Date	Transaction	Phase at deal	Disclosed economics
2025-04-01	Oliva Therapeutics and Jerome Stevens Pharmaceuticals expanded the agreement to include Thyquidity for the treatment of hypothyroidism	Approved	Financial terms not disclosed
	Jerome Stevens Pharmaceuticals Announces Acquisition of Thyquidity® (Levothyroxine Sodium Oral Solution)	Approved	Financial terms not disclosed
2020-12-17	MannKind and Vertice to Co-Promote Thyquidity™ (levothyroxine sodium) Oral Solution	Approved	Financial terms not disclosed

Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.

6. IP and freedom-to-operate screen

The milestone feed surfaced a patent-application signal described as “Levothyroxine sodium orally disintegrating micro-tablet and preparation method thereof”. The milestone feed surfaced a patent-application signal described as “Pharmaceutical oral solid dosage forms including liothyronine and levothyroxine salts and methods of making and using the same”. The milestone feed surfaced a patent-application signal described as “Stable levothyroxine compositions in aprotic polar solvents”.

The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights. Confirm that licensed patents, data and know-how track every granted territory and field.

7. Principal risks and diligence gates

Therapeutic index across KRAS/BRAF mutation subgroups
On-target toxicity and adaptive MAPK resistance
Lack of matched efficacy results in the current MCP result set

Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.

8. Final go/no-go memorandum

GO